Clinical Trials Logo

Preleukemia clinical trials

View clinical trials related to Preleukemia.

Filter by:

NCT ID: NCT06143839 Recruiting - Clinical trials for Acute Myeloid Leukemia (AML)

VYxeoS Liposomal Italian Observational Study iN the Real Practice

VYSION
Start date: December 7, 2023
Phase:
Study type: Observational

The study is a prospective, single-arm, non-experimental, observational study in patients in Italy with Acute Myeloid Leukaemia (AML) with myelodysplastic-related changes or therapy related AML initiating treatment with JZP351 (Vyxeos liposomal) in their normal clinical practice.

NCT ID: NCT06138587 Recruiting - Leukemia Clinical Trials

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

Start date: January 24, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to test the safety and efficacy of cytokine induced memory-like (CIML) natural killer (NK) cells expanded with Interleukin-2 (IL-2) at preventing relapse in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or MDS and myeloproliferative neoplasm (MPN) overlap syndrome after a standard-of-care stem cell transplant. Names of the study therapies involved in this study are: - CIML NK cells intravenous infusion (cellular therapy) - Subcutaneous Interleukin-2 (recombinant, human glycoprotein)

NCT ID: NCT06113302 Recruiting - Clinical trials for Myelodysplastic Syndromes

A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)

Start date: March 1, 2024
Phase: Early Phase 1
Study type: Interventional

To learn if luspatercept is more effective in helping to reduce the number of blood transfusions needed by patients with LR-MDS.

NCT ID: NCT06109064 Recruiting - Clinical trials for Myelodysplastic Syndromes

Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk MDS

Start date: October 27, 2023
Phase: Phase 2
Study type: Interventional

This study aimed to evaluate the safety and efficacy of unrelated umbilical cord blood microtransplantation in the treatment of above-mentioned MDS patients by observing the factors related to the efficacy and adverse reactions.

NCT ID: NCT06091267 Recruiting - Clinical trials for Myelodysplastic Syndromes

PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes

Start date: October 16, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is an Open-Label, Crossover, Pharmacokinetic and Efficacy Bridging Study of Oral ASTX727 versus IV Decitabine in Chinese Subjects with Myelodysplastic Syndromes

NCT ID: NCT06073860 Recruiting - Clinical trials for Myelodysplastic Syndrome

A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia

Start date: November 2, 2023
Phase:
Study type: Observational

The purpose of this observational study is to assess the real-world safety of luspatercept in Korean participants with myelodysplastic syndrome (MDS) or beta thalassemia. Investigators will enroll participants who will begin treatment with at least 1 dose of luspatercept.

NCT ID: NCT06063486 Recruiting - Clinical trials for Myelodysplastic Syndrome

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

Start date: March 1, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial evaluates how a curcumin supplement (C3 complex/Bioperine) changes the inflammatory response and symptomatology in patients with clonal cytopenia of undetermined significance (CCUS), low risk myelodysplastic syndrome (LR-MDS), and myeloproliferative neoplasms (MPN). Chronic inflammation drives disease development and contributes to symptoms experienced by patients with CCUS, LR-MDS, and MPN. Curcumin has been shown to have anti-inflammatory and anti-cancer properties and has been studied in various chronic illnesses and hematologic diseases.

NCT ID: NCT06046313 Recruiting - Clinical trials for Acute Myeloid Leukemia

Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS

Start date: October 19, 2023
Phase: Phase 2
Study type: Interventional

To explore the efficacy and safety of prolonged low-dose decitabine (10 days of 6mg/m2) plus venetoclax (3 weeks/cycle) regimen in primary diagnosed elderly or frail AML/ high-risk MDS.

NCT ID: NCT06045689 Recruiting - Clinical trials for Myelodysplastic Syndromes

A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants

MAXILUS
Start date: October 5, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Luspatercept when administered at the maximum approved dose in low-risk Myelodysplastic Syndrome participants who require red blood cell transfusions.

NCT ID: NCT06001385 Recruiting - Lymphoma Clinical Trials

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

OPTIMIZE
Start date: December 8, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question[s] it aims to answer are: - Does a reduced dose of PTCy reduce the occurrence of infections in the first 100 days after transplant? - Does a reduced dose of PTCy maintain the same level of protection against Graft Versus Host Disease (GvHD) as the standard dose of PTCy?